Compared with AI group, toremifene group exhibited a younger age, a higher proportion of patients without lymph node metastasis, at stage I, HER2‐negative, with ER expression of ≤20%, at moderate risk, and without chemotherapy (Table 1). This evidence concerns the gene ESR1 and metastatic malignant neoplasm in the lymph nodes.